Search Results

There are 21017 results for: content related to: Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

  1. Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir-Boosted Saquinavir in HIV-1-Infected Patients

    The Journal of Clinical Pharmacology

    Volume 44, Issue 7, July 2004, Pages: 793–802, Dr. Kiat Ruxrungtham, Mr. Mark Boyd, Dr. S. Eralp Bellibas, Dr. Xiaoping Zhang, Dr. Albert Dorr, Mr. Stanley Kolis, Dr. Tosca Kinchelow, Dr. Neil Buss and Dr. Indravadan H. Patel

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270004266489

  2. You have free access to this content
    Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin

    British Journal of Clinical Pharmacology

    Volume 73, Issue 5, May 2012, Pages: 758–767, Chao Zhang, Paolo Denti, Eric Decloedt, Gary Maartens, Mats O. Karlsson, Ulrika S. H. Simonsson and Helen McIlleron

    Version of Record online : 5 APR 2012, DOI: 10.1111/j.1365-2125.2011.04154.x

  3. You have free access to this content
    JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

    Hepatology Research

    Volume 46, Issue 2, February 2016, Pages: 129–165, Yasuhiro Asahina, Namiki Izumi, Kumada Hiromitsu, Masayuki Kurosaki, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Eiji Tanaka, Yasuhito Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu and Hiroshi Yotsuyanagi

    Version of Record online : 15 FEB 2016, DOI: 10.1111/hepr.12645

  4. Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies

    The Journal of Clinical Pharmacology

    Volume 46, Issue 2, February 2006, Pages: 130–139, Marta Boffito, Desmond Maitland and Anton Pozniak

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005283279

  5. Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: I. Evidence Against CYP3A Mediation of Methadone Clearance

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 4, October 2008, Pages: 497–505, ED Kharasch, PS Bedynek, S Park, D Whittington, A Walker and C Hoffer

    Version of Record online : 9 JUL 2008, DOI: 10.1038/clpt.2008.104

  6. You have free access to this content
    Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 714A–807A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28228

  7. Time-Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine

    The Journal of Clinical Pharmacology

    Volume 46, Issue 7, July 2006, Pages: 758–767, P. G. Rolf, Dr van Heeswijk, Mr Marc Bourbeau, Ms Pearl Campbell, Ms Isabelle Seguin, Mr Bobby M. Chauhan, Dr Brian C. Foster and Dr D. William Cameron

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006288733

  8. Steady-State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in Healthy HIV-Negative Volunteers

    The Journal of Clinical Pharmacology

    Volume 53, Issue 2, February 2013, Pages: 202–210, Monika Schöller-Gyüre, Thomas N. Kakuda, James Witek, Sophie H. Akuma, Goedele De Smedt, Kurt Spittaels, Veerle Vyncke and Richard M.W. Hoetelmans

    Version of Record online : 24 JAN 2013, DOI: 10.1177/0091270012445205

  9. You have free access to this content
    Enhanced Boosting of Oral Absorption of Lopinavir Through Electrospray Coencapsulation with Ritonavir

    Journal of Pharmaceutical Sciences

    Volume 104, Issue 9, September 2015, Pages: 2977–2985, Shinji Sakuma, Satoshi Matsumoto, Narimoto Ishizuka, Kohta Mohri, Mayuko Fukushima, Chie Ohba and Kohsaku Kawakami

    Version of Record online : 18 MAY 2015, DOI: 10.1002/jps.24492

  10. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  11. Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir-Enhanced Tipranavir

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 6, June 2007, Pages: 888–909, Dr. Manoli Vourvahis and Dr. Angela D. M. Kashuba

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.27.6.888

  12. Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P-Glycoprotein Activities

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 4, October 2008, Pages: 506–512, ED Kharasch, PS Bedynek, A Walker, D Whittington and C Hoffer

    Version of Record online : 9 JUL 2008, DOI: 10.1038/clpt.2008.102

  13. Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone

    The Journal of Clinical Pharmacology

    Volume 43, Issue 4, April 2003, Pages: 414–422, David J. Greenblatt, Lisa L. von Moltke, Jerold S. Harmatz, Steven M. Fogelman, Gengsheng Chen, Jennifer A. Graf, Polyxane Mertzanis, Susan Byron, Kerry E. Culm, Brian W. Granda, Johanna P. Daily and Richard I. Shader

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003251864

  14. Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure

    Clinical Pharmacology & Therapeutics

    Volume 85, Issue 1, January 2009, Pages: 64–70, AA Mathias, S West, J Hui and BP Kearney

    Version of Record online : 24 SEP 2008, DOI: 10.1038/clpt.2008.168

  15. You have full text access to this OnlineOpen article
    Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged 3 to <12 Years

    CPT: Pharmacometrics & Systems Pharmacology

    Volume 4, Issue 7, July 2015, Pages: 406–414, A Brochot, TN Kakuda, T Van De Casteele, M Opsomer, FL Tomaka, A Vermeulen and P Vis

    Version of Record online : 19 JUN 2015, DOI: 10.1002/psp4.44

  16. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor

    Journal of Viral Hepatitis

    Volume 20, Issue 11, November 2013, Pages: 779–789, J. de Bruijne, X. V. Thomas, S. P. Rebers, C. J. Weegink, M. A. Treitel, E. Hughes, J. F. Bergmann, R. J. de Knegt, H. L. A. Janssen, H. W. Reesink, R. Molenkamp and J. Schinkel

    Version of Record online : 27 JUN 2013, DOI: 10.1111/jvh.12104

  17. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir

    Journal of Pharmaceutical Sciences

    Volume 100, Issue 6, June 2011, Pages: 2508–2515, Rob ter Heine, Robert A. B. Van Waterschoot, Ron J. Keizer, Jos H. Beijnen, Alfred H. Schinkel and Alwin D. R. Huitema

    Version of Record online : 29 DEC 2010, DOI: 10.1002/jps.22457

  18. Thorough QT/QTc Study of Ritonavir-Boosted Saquinavir Following Multiple-Dose Administration of Therapeutic and Supratherapeutic Doses in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 52, Issue 4, April 2012, Pages: 520–529, Dr Xiaoping Zhang, Dr Paul Jordan, Ms Laura Cristea, Dr Miklos Salgo, Ms Rana Farha, Mr Stanley Kolis and Dr Lois S. Lee

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011400071

  19. Ritonavir Has Minimal Impact on the Pharmacokinetic Disposition of a Single Dose of Bupropion Administered to Human Volunteers

    The Journal of Clinical Pharmacology

    Volume 46, Issue 5, May 2006, Pages: 567–576, Dr Leah M. Hesse, Dr David J. Greenblatt, Dr Lisa L. von Moltke and Dr Michael H. Court

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006286981

  20. The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 51, Issue 2, February 2011, Pages: 237–242, Dr Ivy Song, Dr Sherene S. Min, Ms Julie Borland, Ms Yu Lou, Dr Shuguang Chen, Dr Parul Patel, Dr Toru Ishibashi and Dr Stephen C. Piscitelli

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010371113